Publications by Professor Nicola Curtin - ePrints

Browsing publications by Professor Nicola Curtin.

Newcastle Authors	Title	Year
Hannah Smith Dr Elaine Willmore Dr Lisa Prendergast Professor Nicola Curtin	ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors	2024
Dr Nicola Johnson Dr Johanne Bentley Lan Wang Professor Craig Robson Professor Nicola Curtin et al.	Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells (British Journal of Cancer, (2010), 102, 2, (342-350), 10.1038/sj.bjc.6605479)	2024
Maryam Zanjirband Zanjirband Professor Nicola Curtin Professor John Lunec	Erratum: Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer (Oncotarget (2017) 8 41 (69779-69796))	2024
Professor Nicola Curtin	The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19	2024
Dr Santu Saha Dr Stuart Rundle Dr Ioannis Kotsopoulos Dr Jake Begbie Rachel Howarth et al.	Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy	2022
Hannah Smith Dr Elaine Willmore Dr Asima Mukhopadhyay Dr Yvette Drew Professor Nicola Curtin et al.	Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling	2022
Dr Christopher Morris Professor Nicola Curtin	Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations	2022
Alice Bradbury Professor Nicola Curtin Dr Yvette Drew	The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response	2022
Dr Sweta Sharma Saha Lucy Gentles Dominik Brecht Dr Rachel O'Donnell Professor Nicola Curtin et al.	Genomic, transcriptomic, and functional alterations in DNA damage response pathways as putative biomarkers of chemotherapy response in ovarian cancer	2021
Harriet Southgate Dr Lindi Chen Professor Nicola Curtin Professor Deborah Tweddle	Increased replication stress determines ATR inhibitor sensitivity in neuroblastoma cells	2021
Lucy Gentles Professor Nicola Curtin Dr Yvette Drew Dr Rachel O'Donnell	Integration of computer-aided automated analysis algorithms in the development and validation of immunohistochemistry biomarkers in ovarian cancer	2021
Harriet Southgate Dr Lindi Chen Professor Deborah Tweddle Professor Nicola Curtin	ATR inhibition potentiates parp inhibitor cytotoxicity in high risk neuroblastoma cell lines by multiple mechanisms	2020
Alice Bradbury Dr Rachel O'Donnell Dr Yvette Drew Professor Nicola Curtin Dr Sweta Sharma Saha et al.	Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of genomic, transcriptomic, proteomic and functional DNA damage response biomarkers for therapeutic targeting	2020
Hannah Smith Harriet Southgate Professor Deborah Tweddle Professor Nicola Curtin	DNA damage checkpoint kinases in cancer	2020
Dr Santu Saha Rachel Howarth Dr Isabel Pappworth Lucy Gentles Professor Kevin Marchbank et al.	Exploring rucaparib as chemo-radiosensitiser to increase therapeutic ratio in cervical cancer.	2020
Hannah Smith Dr Lisa Prendergast Professor Nicola Curtin	Exploring the synergy between PARP and CHK1 inhibition in matched BRC2 mutant and corrected cells	2020
Dr Santu Saha Rachel Howarth Professor Kevin Marchbank Professor Nicola Curtin	Increasing the therapeutic index of radiation by combination with rucaparib in cervical cancer.	2020
Professor Nicola Curtin	Poly(ADP-ribose) polymerase inhibition: past, present and future	2020
Dr Santu Saha Rachel Howarth Dr Isabel Pappworth Professor Kevin Marchbank Professor Nicola Curtin et al.	Potential use of the PARP inhibitor rucaparib to enhance cervical cancer treatment.	2020
Professor Nicola Curtin	Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?	2020
Alice Bradbury Sally Hall Professor Nicola Curtin Dr Yvette Drew	Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?	2020
Harriet Southgate Dr Lindi Chen Professor Nicola Curtin Professor Deborah Tweddle	Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma	2020
Professor Nicola Curtin	The development of Rucaparib/Rubraca(R): a story of the synergy between science and serendipity	2020
Dr Asima Mukhopadhyay Dr Yvette Drew Liz Matheson Dr Mo Salehan Lucy Gentles et al.	Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors	2019
Lucy Gentles Bojidar Goranov Elizabeth Matheson Dr Ashleigh Herriott Dr Angelika Kaufmann et al.	Exploring the frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types	2019
Judith Unterlass Professor Nicola Curtin	Warburg and Krebs and related effects in cancer	2019
Professor Nicola Curtin Dr Yvette Drew Dr Sweta Sharma Saha	Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy	2019
Lucy Gentles Liz Matheson Dr Nicholas Bown Alice Bradbury Maryam Zanjirband Zanjirband et al.	Characterization and drug sensitivity of a novel human overian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor	2018
Dr Sarah Fordham Dr Helen Blair Dr Claire Elstob Professor Ruth Plummer Dr Yvette Drew et al.	Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase	2018
Professor Nicola Curtin	Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases	2018
Fiona Middleton Professor Nicola Curtin	The impact of p53 dysfunction in ATR inhibitor cytotoxicity and chemo-and radiosensitisation	2018
Judith Unterlass Dr Arnaud Basle Dr Julie Tucker Dr Celine Cano Professor Martin Noble et al.	Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer	2018
Lucy Gentles Dr Calum Kirk Huw Thomas Professor Steve Wedge Professor Nicola Curtin et al.	An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer	2017
Maryam Zanjirband Zanjirband Professor Nicola Curtin Professor John Lunec	Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer	2017
Dr Aiste McCormick Dr Peter Donoghue Michelle Dixon Dr Rachel O'Donnell James Murray et al.	Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib	2017
Dr Miranda Patterson Dr Yvette Drew Professor Nicola Curtin	PARP	2017
Carlo Bawn Dr Martin Galler Huw Thomas Suzanne Kyle Professor Nicola Curtin et al.	PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS	2017
Dr Ashleigh Herriott Dr Miranda Patterson Professor Nicola Curtin	Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers	2017
Dr Britta Vormoor Yvonne Schlosser Dr Helen Blair Abhishek Sharma Sarah Wilkinson et al.	Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2	2017
Professor Nicola Curtin	Strategies Employed for the Development of PARP Inhibitors	2017
Judith Unterlass Dr Arnaud Basle Dr Julie Tucker Dr Celine Cano Professor Martin Noble et al.	Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH)	2017
Dr Ganiy Abdulrahman Professor Nicola Curtin	Targeting DNA Damage Response Pathways in Cancer	2017
Dr Stuart Rundle Alice Bradbury Dr Yvette Drew Professor Nicola Curtin	Targeting the ATR-CHK1 Axis in Cancer Therapy	2017
Professor Nicola Curtin	The use of PARP inhibitors in cancer therapy: Use as adjuvant with chemotherapy or radiotherapy, use as a single agent in susceptible patients, and techniques used to identify susceptible patients	2017
Dr Rachel O'Donnell Dr Angelika Kaufmann Dr Laura Woodhouse Dr Aiste McCormick Professor Richard Edmondson et al.	Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity	2016
Dr Peter Stephens Professor Nicola Curtin	Chk1 phosphorylated at serine³⁴⁵ is a predictor of early local recurrence and radio-resistance in breast cancer	2016
Barry Dent Laura Ogle Dr Rachel O'Donnell Dr Ujjal Mallick Professor Nicola Curtin et al.	High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers	2016
Laura Ogle Dr James Orr Dr Catherine Willoughby Dr Claire Hutton Professor Stuart McPherson et al.	Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?	2016
Dr Ioannis Kotsopoulos Dr Asima Mukhopadhyay Professor John Lunec Professor Nicola Curtin Ali Kucukmetin et al.	IN VITRO SINGLE AGENT RUCAPARIB CYTOTOXICITY AND CISPLATIN CHEMO-POTENTIATION IN CERVICAL CANCER CELL LINES	2016
Dr Ganiy Abdulrahman Elizabeth Matheson Dr Yvette Drew Professor Nicola Curtin Dr Asima Mukhopadhyay et al.	Investigating PARP inhibitor sensitisation by hyperthermia and HSP90 inhibition	2016
Dr Peter Stephens Professor Ruth Plummer Professor Nicola Curtin	mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition	2016
Dr Yvette Drew Dr Martin Highley Julieann Sludden Dr James Murray Dr David Jamieson et al.	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer	2016
Dr Ioannis Kotsopoulos Ali Kucukmetin Dr Asima Mukhopadhyay Professor John Lunec Professor Nicola Curtin et al.	Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis Mechanism and Potential Role for PARP Inhibitors	2016
Elizabeth Matheson Dr Mo Salehan Dr Asima Mukhopadhyay Professor Nicola Curtin Dr Yvette Drew et al.	Preclinical studies of the PARP inhibitor olaparib in combination with imatinib in BRCA stratified ovarian cancer	2016
Professor Nicola Curtin	Biomarkers for parp inhibitors	2015
Dr Arman Esfandiari Professor Nicola Curtin Professor John Lunec	Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner	2015
Fiona Middleton Dr Miranda Patterson Dr Claire Elstob Dr Sarah Fordham Dr Ashleigh Herriott et al.	Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition	2015
Dr Aiste McCormick Dr Peter Donoghue Michelle Dixon Dr Rachel O'Donnell Dr Angelika Kaufmann et al.	Defects in non-homologous end joining pathway in ovarian cancers results in resistance to rucaparib	2015
Dr Tao Chen Fiona Middleton Professor Nicola Curtin	Development of pharmacodynamic biomarkers for ATR inhibitors	2015
Liam Cornell Dr Joanne Martin Laura Ogle Dr Catherine Willoughby Dr Despina Televantou et al.	DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival	2015
Dr James Murray Julieann Sludden Professor Alan Boddy Professor Nicola Curtin	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System	2015
Dr Britta Vormoor Yvonne Schlosser Dr Helen Blair Sarah Wilkinson Professor Herbie Newell et al.	Inhibition of DNA-Repair Enzymes (DNA-Pk and Parp) to Sensitize Ewing Sarcoma to Chemo-And Radiotherapy	2015
Dr Rachel O'Donnell Dr Angelika Kaufmann Dr Aiste McCormick Professor Nicola Curtin Professor Richard Edmondson et al.	Intra- and inter-tumour heterogeneity in epithelial ovarian cancer: consequences for biomarker dependent stratification of therapies	2015
Professor Nicola Curtin	PARP Activity in Peripheral Blood Lymphocytes as a Predictive Biomarker for PARP Inhibition in Tumor Tissues - A Population Pharmacokinetic/Pharmacodynamic Analysis of Rucaparib	2015
Dr Ashleigh Herriott Dr Susan Tudhope Gesa Junge Natalie Rodrigues Dr Miranda Patterson et al.	PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia	2015
Dr Aiste McCormick Dr Sirintra Nakjang Dr Peter Donoghue Professor Nicola Curtin Professor Richard Edmondson et al.	The role of homologous recombination recovery in cisplatin and rucaparib resistance in ovarian cancer	2015
Judith Unterlass Nabila Aljufri Sophie Bex Dr Celine Cano Professor Martin Noble et al.	Towards structure-based drug design of 3-phosphoglycerate dehydrogenase inhibitors	2015
Fiona Middleton Dr Tao Chen Professor Nicola Curtin	Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer	2015
Huw Thomas Professor Nicola Curtin	Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself	2015
Dr Miranda Patterson Dr Ian Forrest Becci Sharrock Maria Lane Dr Angelika Kaufmann et al.	Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples	2014
Barry Dent Dr Rachel O'Donnell Laura Ogle Padmini Ramesh Nick Hayes et al.	Detection and characterization of circulating tumor cells by imaging flow cytometry	2014
Dr Laura Ogle Dr David Jamieson Dr Rachel O'Donnell Barry Dent Professor Nicola Curtin et al.	Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStream^x	2014
Wojciech Ciszewski Dr Michele Tavecchio Professor Nicola Curtin	DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin	2014
Dr Asima Mukhopadhyay Michelle Dixon Dr Evan Mulligan James Murray Professor Nicola Curtin et al.	Evaluation of different methods to assess homologous recombination status and sensitivity to parp inhibitors in ovarian cancer	2014
Dr Stephany Veuger Professor Nicola Curtin	Inhibition of DNA Repair as a Therapeutic Target	2014
Fiona Middleton Dr Tao Chen Professor Nicola Curtin	Investigating p53 and other potential determinants of cell sensitivity to ATR inhibition by VE-821	2014
Professor Nicola Curtin Professor Rakesh Heer	Investigating PARP-1 expression and activity in male and female, benign and malignant renal tissue	2014
Professor Richard Edmondson Dr Asima Mukhopadhyay Professor Nicola Curtin	Molecular characterization of matched ovarian ascites and tumors suggests multiple mechanisms for a homologous recombination defective phenotype	2014
Fiona Middleton Dr Tao Chen Professor Nicola Curtin	p53 and other components of the DNA damage response as determinants of cell sensitivity to ATR inhibition	2014
Professor Nicola Curtin	PARP inhibitors for anticancer therapy	2014
Professor Nicola Curtin	PARP inhibitors target ATM+p53-defective gastric cancer	2014
Dr Britta Vormoor Professor Nicola Curtin	Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma	2014
Pawel Znojek Dr Elaine Willmore Professor Nicola Curtin	Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase	2014
Dr Rachel O'Donnell Dr Aiste McCormick Dr Asima Mukhopadhyay Michelle Dixon Dr Angelika Kaufmann et al.	The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis	2014
James Murray Huw Thomas Philip Berry Suzanne Kyle Dr Miranda Patterson et al.	Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules	2014
Dr Celine Cano Dr Kappusamy Saravanan Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK PI3-K Inhibitory Activity	2013
Professor Ruth Plummer Dr Evan Mulligan Professor Nicola Curtin Professor Alan Calvert	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation	2013
Anna Whitehead Dr Gillian Patman Liam Cornell Dr Despina Televantou Professor Nicola Curtin et al.	A Role for DNA Repair Protein Kinase (DNA-PK) in the Progression of Simple Steatosis to Steatohepatitis (NASH)?	2013
Fiona Middleton Professor Nicola Curtin	ATR as a therapeutic target	2013
Professor Nicola Curtin	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer	2013
Dr Tommy Rennison Sonsoles Rodriguez-Aristegui Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)	2013
Professor Nicola Curtin	First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors	2013
Dr Rachel O'Donnell Laura Woodhouse Dr Aiste McCormick Dr Asima Mukhopadhyay Michelle Dixon et al.	Functional Intra-Tumour Heterogeneity in Ovarian Cancer: What is a Representative Tumour Sample?	2013
Professor Nicola Curtin	Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer	2013
Dr Aiste McCormick Professor Nicola Curtin Professor Richard Edmondson	Inhibition of DNA-PK Recovers HR Function and Results in Platinum Resistance in an Ovarian Cancer Cell Line Model	2013
Dr Miranda Patterson Professor Nicola Curtin	Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies	2013
Michael Batey Dr Yan Zhao Suzanne Kyle Professor Herbie Newell Professor Nicola Curtin et al.	Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer	2013
Dr Rachel O'Donnell Barry Dent Laura Ogle Professor Nicola Curtin Dr David Jamieson et al.	The Characterisation and Functional Assessment of Epithelial Ovarian Cancer Cells Derived from Ascitic Fluid using Imagestream	2013
Professor Nicola Curtin	Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond	2013
Fiona Middleton Dr Tao Chen Professor Nicola Curtin	Chemosensitisation By, and Single Agent Activity of, ATR Inhibitor VE-821 in Human Breast Cancer Cells	2012
Dr Joanne Martin Michael Batey Dr Yan Zhao Dr Celine Cano Dr Michele Tavecchio et al.	Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K	2012
Dr Asima Mukhopadhyay Professor Ruth Plummer Dr Ahmed Elattar Dr San Soo Hoo Bisha Uzir et al.	Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum and survival	2012
Dr Asima Mukhopadhyay Professor Ruth Plummer Dr Ahmed Elattar Dr San Soo Hoo Bisha Uzir et al.	Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum and survival	2012
Dr Asima Mukhopadhyay Professor Ruth Plummer Dr Ahmed Elattar Dr San Soo Hoo Bisha Uzir et al.	Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival	2012
Dr Aiste McCormick Dr Asima Mukhopadhyay Professor Ruth Plummer Professor Nicola Curtin Professor Richard Edmondson et al.	Defective homologous recombination in human cancers	2012
Professor Nicola Curtin	DNA repair dysregulation from cancer driver to therapeutic target	2012
Liam Cornell Dr Joanne Martin Professor Nicola Curtin Professor Helen Reeves	DNA-PK or ATM inhibition inhibits non-homologous end joining and enhances chemo- and radio sensitivity in hepatocellular cancer cell lines	2012
Dr Britta Vormoor Sarah Wilkinson Fiona Harvey Professor Ruth Plummer Professor Nicola Curtin et al.	Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699)	2012
Dr Michele Tavecchio Dr Joanne Martin Dr Celine Cano Professor Herbie Newell Professor Nicola Curtin et al.	Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination	2012
Dr Elaine Willmore Natalie Rodrigues Dr Jonathan Wallis Professor Nicola Curtin	High Activity of Poly(ADP-Ribose) Polymerase in Chronic Lymphocytic Leukemia	2012
Dr Aiste McCormick Professor Nicola Curtin Professor Richard Edmondson	Non homologous end joining assessment in ovarian cancer	2012
Professor Nicola Curtin	Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors	2012
Dr Miranda Patterson James Murray Professor Nicola Curtin	Stability of PARP Inhibition by BMN 673 in Human PBMCs (and Leukaemic Cell Cultures)	2012
Dr Tao Chen Dr Peter Stephens Fiona Middleton Professor Nicola Curtin	Targeting the S and G2 checkpoint to treat cancer	2012
Professor Nicola Curtin	The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients	2012
Professor Nicola Curtin	Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design	2012
Dr Jody Barbeau Professor Nicola Curtin	Visualization of a DNA-PK/PARP1 complex	2012
Huw Thomas Professor Herbie Newell Professor Nicola Curtin	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition	2011
Dr Amy Peasland Dr Tao Chen Professor Richard Edmondson Professor Nicola Curtin	Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines	2011
Dr Kappusamy Saravanan Hannah Barlow Marion Barton Professor Hilary Calvert Emeritus Professor Bernard Golding et al.	Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α₁-Acid Glycoprotein	2011
Dr Asima Mukhopadhyay Professor Nicola Curtin Professor Ruth Plummer Professor Richard Edmondson	PARP Inhibitors And Epithelial Ovarian Cancer: An Approach To Targeted Chemotherapy And Personalized Medicine	2011
Tomasz Zaremba Huw Thomas Mike Cole Dr Sally Coulthard Professor Ruth Plummer et al.	Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers	2011
Huw Thomas Dr Celine Roche Dr Johanne Bentley Dr Ian Hardcastle Emeritus Professor Bernard Golding et al.	Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301	2011
Professor Nicola Curtin	Strategies employed for the development of PARP inhibitors	2011
Dr Fadhel Shaheen Pawel Znojek Dr Ann Fisher Professor Ruth Plummer Dr Luke Gaughan et al.	Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer	2011
Huw Thomas Suzanne Kyle Ivanda Pavlovska Professor Nicola Curtin	The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice	2011
Professor Nicola Curtin	The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy	2011
Professor Nicola Curtin	The role of PARP in DNA repair and its therapeutic exploitation	2011
Dr Yvette Drew Dr Evan Mulligan Wan Vong Huw Thomas Suzanne Kyle et al.	Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2	2011
Huw Thomas Suzanne Kyle Rafal Zur Dr Evan Mulligan Professor Nicola Curtin et al.	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance	2010
Rachel Daniel Dr Agata Rozanska Dr Evan Mulligan Dr Yvette Drew Huw Thomas et al.	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699	2010
Dr Asima Mukhopadhyay Dr Ahmed Elattar Dr Aiste McCormick Sarah Wilkinson Dr Yvette Drew et al.	Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors	2010
Dr Kate Smith Dr Tommy Rennison Sonsoles Rodriguez-Aristegui Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)	2010
Dr Celine Cano Dr Olivier Barbeau Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype	2010
Tomasz Zaremba Huw Thomas Mike Cole Professor Ruth Plummer Professor Nicola Curtin et al.	Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials	2010
Dr Nicola Johnson Dr Johanne Bentley Lan Wang Professor Herbie Newell Professor Craig Robson et al.	Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells	2010
Dr Britta Vormoor Professor Nicola Curtin Professor Steven Clifford	Sensitisation of paediatric solid tumours to DNA-damaging chemotherapy by inhibition of DNA-dependent protein kinase (PRKDC)	2010
Dr Francesco Marchetti Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Synthesis and biological evaluation of 5-substituted O⁴-alkylpyrimidines as CDK2 inhibitors	2010
Liam Cornell Dr Joanne Martin Febrina Budhisetiawan Professor Herbie Newell Professor Derek Manas et al.	Synthetic lethality in liver cancer cell lines treated with inhibitors of DNA double strand break repair	2010
Dr Agata Rozanska Dr Evan Mulligan Huw Thomas Deborah Castelbuono Professor Deborah Tweddle et al.	[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-014699	2009
Professor Nicola Curtin	[abstract] Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked	2009
Dr Evan Mulligan Tomasz Zaremba Dr Yvette Drew Professor Ruth Plummer Professor Nicola Curtin et al.	[abstract] Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes	2009
Dr Evan Mulligan Professor Nicola Curtin Professor Ruth Plummer	Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines	2009
Huw Thomas Professor Nicola Curtin	Exploiting Homologous recombination repair defects in cancer cells	2009
Dr Agata Rozanska Huw Thomas Dr Evan Mulligan Dr Yvette Drew Deborah Castelbuono et al.	Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma	2009
Professor Nicola Curtin	Poly(ADP-Ribose) Polymerase-1 and DNA-Dependent Protein Kinase Have Equivalent Roles in Double Strand Break Repair Following Ionizing Radiation	2009
Tomasz Zaremba Professor Ruth Plummer Dr Sally Coulthard Mike Cole Professor Nicola Curtin et al.	Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in a panel of human tumor cell lines [abstract]	2009
Tomasz Zaremba Mike Cole Dr Sally Coulthard Professor Ruth Plummer Professor Nicola Curtin et al.	Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines	2009
Huw Thomas Dr Kappusamy Saravanan Lan Wang Mei Lin Dr Julian Scott Northen et al.	Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity	2009
Huw Thomas Suzanne Kyle Tim Robson Professor Nicola Curtin	Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?	2009
Professor Herbie Newell Huw Thomas Lan Wang Dr Celine Roche Dr Ian Hardcastle et al.	[abstract] Preclinical in vitro and in vivo evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU6301	2008
Neil Johnson Professor Nicola Curtin Dr Andrew Hall	A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer	2008
Dr Celine Cano Emeritus Professor Bernard Golding Dr Ian Hardcastle Professor Nicola Curtin Professor Roger Griffin et al.	8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK)	2008
Huw Thomas Professor Nicola Curtin	Chemosensitisation by tricyclic poly(ADP-ribose) polymerase (PARP) inhibitors in vivo: More than just DNA repair? [abstract]	2008
Michael Batey Professor Herbie Newell Professor Nicola Curtin	Chemosensitisation of cancer cells by KU-0060648, a potent and selective inhibitor of DNA-PK [abstract]	2008
Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Karen Haggerty Dr Ian Hardcastle et al.	Development of Potent Water-soluble Inhibitors of DNA-Dependent Protein Kinase (DNA-PK)	2008
Suzanne Kyle Huw Thomas Dr Jane Mitchell Professor Nicola Curtin	Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer	2008
Dr Kappusamy Saravanan Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Karen Haggerty et al.	Identification of potent water-soluble DNA-dependent protein kinase (DNA-PK) inhibitors using a small-molecule library approach [abstract]	2008
Dr Yvette Drew Suzanne Kyle Professor Richard Edmondson Professor Ruth Plummer Professor Nicola Curtin et al.	Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic cancers? [abstract]	2008
Professor Alan Calvert Professor Ruth Plummer Professor Nicola Curtin Professor Richard Edmondson Dr Yvette Drew et al.	PARP inhibitors in cancer treatment	2008
Professor Alan Calvert Professor Nicola Curtin Professor Ruth Plummer	PARP inhibitors in ovarian cancer	2008
Professor Ruth Plummer Dr Christopher Jones Professor Nicola Curtin Professor Alan Boddy Professor Herbie Newell et al.	Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors	2008
Tomasz Zaremba Mike Cole Dr Sally Coulthard Professor Ruth Plummer Professor Nicola Curtin et al.	Poly(ADP-ribose) polymerase-1 (PARP-1) genomics in relation to activity in healthy volunteers and cancer patients	2008
Michael Batey Dr Laurent Rigoreau Professor Roger Griffin Professor Herbie Newell Professor Nicola Curtin et al.	Potent in vitro and in vivo radiosensitisation by the selective DNA-dependent protein kinase inhibitor KU-0060648 [abstract]	2008
Professor Nicola Curtin	Rationale for and development of PARP inhibitors for cancer therapy	2008
Lan Wang Professor Nicola Curtin Professor Herbie Newell	Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked	2008
Tomasz Zaremba Professor Nicola Curtin	PARP inhibitor development for systemic cancer targeting	2007
Professor Steven Clifford Rachel Daniel Dr Agata Rozanska Huw Thomas Professor Alan Boddy et al.	Preclinical evaluation of the POLY-ADP ribose polymerase 1 (PARP-1) inhibitor AG014699 in combination with topotecan and temozolomide for the treatment of medulloblastoma and neuroblastoma	2007
Huw Thomas Dr Christopher Calabrese Michael Batey Suzanne Kyle Professor Herbie Newell et al.	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial	2007
Jonathan Hollick Dr Laurent Rigoreau Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase	2007
Dr Francesco Marchetti Kerry Louise Sayle Dr Johanne Bentley Professor William Clegg Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 2	2007
Dr Anastasia Hepburn Professor Craig Robson Professor Nicola Curtin	Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer	2007
Professor Nicola Curtin	Therapeutic potential of drugs to modulate DNA repair in cancer	2007
Huw Thomas Dr Christopher Calabrese Professor Herbie Newell Lan Wang Professor Nicola Curtin et al.	Identification of a PARP inhibitor for clinical trial: Preclinical studies	2006
Dr Yan Zhao Huw Thomas Michael Batey Dr Ian Cowell Professor Roger Griffin et al.	Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441	2006
Professor Roger Griffin Andrew Henderson Professor Nicola Curtin Professor Jane Endicott Dr Ian Hardcastle et al.	Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination	2006
Dr Ian Hardcastle Professor Nicola Curtin Justin John James Leahy Martin Stockley Emeritus Professor Bernard Golding et al.	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach	2005
Professor Herbie Newell Professor Roger Griffin Richard Davison Lan Wang Professor Nicola Curtin et al.	Effect of cell cycle inhibition on cisplatin-induced cytotoxicity	2005
Professor Ruth Plummer Professor Alan Boddy Professor Nicola Curtin Professor Herbie Newell Lynsey Robson et al.	Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide	2005
Dr Ian Hardcastle Dr Shafiq Ahmed Professor Alan Calvert Professor Nicola Curtin Gillian Farnie et al.	Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction	2005
Professor Nicola Curtin	PARP inhibitors for cancer therapy	2005
Professor Nicola Curtin	PARP inhibitors for cancer therapy	2005
Professor Roger Griffin Dr YuZhu Cheng Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Potent CDK2 inhibitors generated using a variant of the cope elimination	2005
Dr Allyson Campbell Dr YuZhu Cheng Lan Wang Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation	2005
Andrew Henderson Dr YuZhu Cheng Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Searching for potent CDK2 inhibitors using a variant of the Cope elimination	2005
Huw Thomas Kathleen Parker Suzanne Kyle Professor Nicola Curtin	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase	2005
Professor Ruth Plummer Dr Christopher Jones Professor Alan Boddy Professor Alan Calvert Professor Herbie Newell et al.	Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O⁶-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1	2005
Lisa Smith Dr Elaine Willmore Professor Caroline Austin Professor Nicola Curtin	The novel poly(ADP-ribose) polymerase inhibitor, AG14361 sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks	2005
Dr Jane Mitchell Professor Nicola Curtin	The role of PARP-1 and DNA-PK in the repair of DNA double strand breaks	2005
Dr Christopher Calabrese Michael Batey Professor Alan Calvert Professor barbara Durkacz Suzanne Kyle et al.	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361	2004
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase	2004
Dr Stephany Veuger Professor Nicola Curtin Professor barbara Durkacz	Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair	2004
Dr Stephany Veuger Professor Nicola Curtin Professor barbara Durkacz	Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair	2004
Dr Yan Zhao Dr Susan Jackson Professor Nicola Curtin	Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM	2004
Dr Ian Hardcastle Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin Professor Jane Endicott et al.	N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2	2004
Professor Nicola Curtin Lan Wang Suzanne Kyle Dr Christine Arris Professor barbara Durkacz et al.	Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells	2004
Professor Nicola Curtin Emeritus Professor Bernard Golding Suzanne Kyle Professor Roger Griffin	Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors	2004
Professor Nicola Curtin Hannah Barlow Professor Alan Calvert Richard Davison Emeritus Professor Bernard Golding et al.	Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to α₁-acid glycoprotein	2004
Dr Nicola Johnson Professor Nicola Curtin	The effects of a novel CDK inhibitor on tamoxifen sensitive and resistant breast cancer cell lines	2004
Dr Veronique Mesguiche Rachel Parsons Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin et al.	4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2	2003
Dr Christopher Calabrese Michael Batey Huw Thomas Professor barbara Durkacz Lan Wang et al.	Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies	2003
Dr Stephany Veuger Professor Nicola Curtin Professor barbara Durkacz	Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1	2003
Kerry Louise Sayle Dr Johanne Bentley Professor Alan Calvert Dr YuZhu Cheng Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2	2003
Professor Nicola Curtin Professor Herbie Newell Professor Alan Calvert Professor Roger Griffin Emeritus Professor Bernard Golding et al.	Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors	2003
Dr Julian Scott Northen Professor William Clegg Professor Nicola Curtin Professor Roger Griffin Emeritus Professor Bernard Golding et al.	Controlled stepwise conversion of 2,4,6,8-tetrachloropyrimido-[5,4-d ]pyrimidine into 2,4,6,8-tetrasubstituted pyrimido[5,4-d]pyrimidines	2002
Noel Monks Professor Nicola Curtin Dr Christine Arris Professor Herbie Newell	DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767	2002
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure	2002
Dr Ashleigh Gibson Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin Professor Jane Endicott et al.	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O6-substituted guanine derivatives	2002
Dr Johanne Bentley Dr Christine Arris Professor Nicola Curtin Professor Jane Endicott Dr Ashleigh Gibson et al.	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor	2002
Dr Elaine Willmore Professor Caroline Austin Professor Nicola Curtin	The role of poly(ADP-ribose) polymerase-1 (PARP-1) in the cellular response to topoisomerase I poisons	2002
Dr Xiaomei Lu Julie Errington Professor Nicola Curtin Professor John Lunec Professor Herbie Newell et al.	The impact of p53 status on cellular sensitivity to antifolate drugs	2001
Professor Nicola Curtin Dr Stephen Barton Michael Batey Dr Christopher Calabrese Professor Alan Calvert et al.	Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.	2001
Professor Herbie Newell Professor Alan Calvert Professor Nicola Curtin	Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro	2001
Gordon Taylor Huw Thomas Professor Herbie Newell Professor Nicola Curtin	Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole	2001
Peter Smith Huw Thomas Hannah Barlow Professor Roger Griffin Emeritus Professor Bernard Golding et al.	In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity	2001
Noel Monks Professor Nicola Curtin Professor Herbie Newell	Induction of apoptosis by the ADEPT agent ZD2767: Comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue	2001
Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle et al.	Inhibiting the MDM2-p53 interaction using low molecular weight compounds	2001
Professor Nicola Curtin Dr Andrew Hughes	Pemetrexed disodium, a novel antifolate with multiple targets	2001
Dr Stephany Veuger Professor barbara Durkacz Emeritus Professor Bernard Golding Professor Roger Griffin Professor Herbie Newell et al.	Radiosensitization by novel inhibitors of PARP, PI, and DNA-PK, NU7026, in vitro	2001
Professor Martin Noble Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design	2001
Professor Martin Noble Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Structure based design of a potent inhibitor of cdk2	2001
Lan Wang Professor Nicola Curtin Professor Herbie Newell	Tumor radiosensitization using TBI-361, an inhibitor of poly (ADP-ribose) polymerase (PARP)	2001
Peter Smith Huw Thomas Hannah Barlow Professor Roger Griffin Emeritus Professor Bernard Golding et al.	In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121	2000
Dr Xiaohong Lu Julie Errington Professor Nicola Curtin Professor Alan Boddy Professor Herbie Newell et al.	Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines	2000
Noel Monks Professor Nicola Curtin Professor Herbie Newell	Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)	2000
Professor Nicola Curtin Professor Alan Calvert Professor barbara Durkacz Professor Roger Griffin Emeritus Professor Bernard Golding et al.	Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines.	2000
Dr Christopher Calabrese Professor Nicola Curtin Michael Batey Huw Thomas Suzanne Kyle et al.	Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase	2000
Professor Roger Griffin Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors	2000
Peter Smith Professor Herbie Newell Professor Nicola Curtin	Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport	2000
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson Emeritus Professor Bernard Golding et al.	Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles	2000
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott Emeritus Professor Bernard Golding et al.	Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles	2000
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	O6-substituted guanines and 4-substituted pyrimidines: a novel class of antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.	2000
Lan Wang Suzanne Kyle Alex White Professor Alan Calvert Professor Nicola Curtin et al.	Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines	2000
Professor Roger Griffin Dr Christine Arris Dr Christine Bleasdale Professor Alan Calvert Professor Nicola Curtin et al.	Resistance-modifying agents. 8. Inhibition of O⁶-alkylguanine-DNA alkyltransferase by O⁶-alkenyl-, O⁶-cycloalkenyl-, and O⁶-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O⁶-(1-cyclopentenylmethyl) guanine	2000
Alex White Professor Alan Calvert Professor Nicola Curtin Professor Roger Griffin Professor Herbie Newell et al.	Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase	2000
Hannah Barlow Professor Nicola Curtin Professor Alan Calvert Emeritus Professor Bernard Golding Professor Herbie Newell et al.	Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP)	2000
Dr Johanne Bentley Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott et al.	Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors	2000
Professor Roger Griffin Hannah Barlow Professor Nicola Curtin Professor Alan Calvert Emeritus Professor Bernard Golding et al.	2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP)	1999
Professor Herbie Newell Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.	1999
Professor Nicola Curtin Dr David Turner	Dipyridamole-mediated reversal of multidrug resistance in MRP over- expressing human lung carcinoma cells in vitro	1999
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson Emeritus Professor Bernard Golding et al.	In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors.	1999
Peter Smith Professor Alan Calvert Professor Herbie Newell Professor Nicola Curtin	MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines	1999
Peter Smith Hannah Barlow Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein.	1999
Professor Nicola Curtin Professor Alan Calvert Professor barbara Durkacz Professor Herbie Newell	Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines.	1999
Professor Nicola Curtin Suzanne Kyle Lan Wang Professor barbara Durkacz Professor Roger Griffin et al.	Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors	1999
Professor Nicola Curtin Professor Alan Calvert Emeritus Professor Bernard Golding Professor Roger Griffin Professor Herbie Newell et al.	Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding	1999
Dr Christopher Calabrese Huw Thomas Michael Batey Professor Nicola Curtin Professor Roger Griffin et al.	Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase	1999
Peter Smith Professor Alan Calvert Professor Herbie Newell Professor Nicola Curtin	Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines	1999
Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin Professor Herbie Newell et al.	2-phenylbenzimidazole-4-carboxamides are potent inhibitors of the DNA repair enzyme poly(ADP-ribose)-polymerase (PARP)	1998
Professor Herbie Newell Professor Alan Calvert Professor Anne Dickinson Professor Frederick Campbell Professor Nicola Curtin et al.	Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro	1998
Professor Alan Calvert Professor Herbie Newell Professor Nicola Curtin	Dipyridamole selectively potentiates antipurine antifolates in human tumour cell lines but not normal tissue targets of dose-limiting toxicity	1998
Noel Monks Professor Herbie Newell Professor Nicola Curtin	Induction of apoptosis in LoVo colorectal cells by the ADEPT system ZD2767: A comparison with chlorambucil and a mono-functional ZD2767 analogue	1998
Professor Jane Endicott Professor Martin Noble Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Insights into CDK inhibitor design from X-ray crystallographic studies	1998
Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	O-6-alkylguanines as selective inhibitors of cyclin dependent kinases	1998
Alex White Emeritus Professor Bernard Golding Professor Roger Griffin Professor Nicola Curtin	Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064	1998
Peter Smith Professor Herbie Newell Professor Alan Calvert Professor Nicola Curtin	Potentiation of the in vitro activity of the multi-targeted antifolate MTA (LY231514) by dipyridamole	1998
Professor Roger Griffin Professor Alan Calvert Professor Nicola Curtin Professor Herbie Newell Emeritus Professor Bernard Golding et al.	Resistance-modifying agents. 5.1 Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)	1998
Professor Nicola Curtin	Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage	1997
Professor Nicola Curtin	Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells	1996
Dr Christine Arris Dr Christine Bleasdale Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Mechanism-based inhibition of O-6-methylguanine-DNA methyltransferase.	1996
Professor Roger Griffin Alex White Kenneth Bowman Professor Alan Calvert Professor Nicola Curtin et al.	Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme Poly(ADP-ribose)polymerase	1996
Professor Roger Griffin Professor Nicola Curtin Professor Herbie Newell Emeritus Professor Bernard Golding Professor barbara Durkacz et al.	The Role of Inhibitors of Poly(Adp-Ribose) Polymerase as Resistance-Modifying Agents in Cancer-Therapy	1995
Dr Christine Arris Dr Christine Bleasdale Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Probing the active site and mechanism of action of O-6-methylguanine-DNA methyltransferase with substrate-analogs to (O-6-substituted guanines)	1994
Professor Nicola Curtin	Mechanism of cell-death following thymidylate synthase inhibition - 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth-inhibition following exposure to CB3717 and dipyridamole.	1991
Professor Nicola Curtin	Dipyridamole enhances increased intracellular DUTP and DNA strand breakage in A549 (human lung-carcinoma) cells treated with CB3717	1990
Professor Nicola Curtin	A radioimmunoassay for deoxythymidine triphosphate	1989
Professor Nicola Curtin Professor Herbie Newell	Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole.	1989
Professor Nicola Curtin	The quantitation by radioimmunoassay of 2'-deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhabited cells	1989
Professor Nicola Curtin	Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.	1988
Professor Margaret Bassendine Professor Nicola Curtin Dr Henry Loose Emeritus Professor Oliver James	Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study.	1987
Professor Nicola Curtin	The quantification of 2'-deoxyuridine 5'-triphosphate in antifolate treated cells using a sensitive radioimmunoassay	1987
Professor Margaret Bassendine Professor Nicola Curtin Emeritus Professor Oliver James	A new thymidylate synthase (TS) inhibitor, CB3717, in human primary liver cancer (PLC) - invitro, xenograft and phase-II studies	1986
Professor Margaret Bassendine Professor Nicola Curtin Emeritus Professor Oliver James	Induction of remission in primary liver cell cancer PLC with a new thymidylate synthase inhibitor, CB3717: a phase II study	1986
Professor Nicola Curtin Emeritus Professor Oliver James Professor Margaret Bassendine	Inhibition of the growth of human hepatocellular-carcinoma invitro and in athymic mice by a quinazoline inhibitor of thymidylate suntjase, CB3717	1986
Emeritus Professor Oliver James Professor Nicola Curtin Professor Margaret Bassendine	Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody	1986
Emeritus Professor Oliver James Professor Margaret Bassendine Professor Nicola Curtin	Localization of primary hepatocellular carcinoma by a radiolabeled monoclonal antibody	1985
Emeritus Professor Oliver James Professor Margaret Bassendine Professor Nicola Curtin	Primary hepatocellular carcinoma localization using a radiolabeled monoclonal antibody	1985
Professor Margaret Bassendine Emeritus Professor Oliver James Professor Nicola Curtin	Localization of primary hepatocellular carcinoma using a radiolabeled monoclonal antibody	1984
Professor Nicola Curtin	Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivo	1983
Professor Margaret Bassendine Professor Nicola Curtin Emeritus Professor Oliver James	Successful treatment of human primary liver cancer xenograft by new quinazoline anti folate agent CB 3717	1983
Professor Nicola Curtin	Changes in developmental-specific enzyme activities during experimental hepatocarcinogenesis in the rat in vivo	1980
Professor Nicola Curtin	Effect of chronic N,N-diethylnitrosamine on the excision of O⁶-ethylguanine from rat liver DNA	1979